Shares of Novo Nordisk (NVO) have received a huge boost this year amid positive headlines for Ozempic, its GLP-1 diabetes/anti-obesity drug. Meanwhile, the S&P Select Food and Beverage Index (SPSIFB) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results